This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: Dabigatran (150 mg twice daily) has been associated with lower …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Importance It remains unclear whether dabigatran etexilate mesylate is associated with
higher risk of bleeding than warfarin sodium in real-world clinical practice. Objective To …

Objectives: The aim of this study was to assess the efficacy and safety in an “everyday
clinical practice” population of anticoagulant-naïve patients with atrial fibrillation (AF) treated …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

For years, warfarin and aspirin have been standard therapies for prophylaxis of stroke in
atrial fibrillation. In late 2010, dabigatran, an oral direct thrombin inhibitor, became available …

Dabigatran is approved for stroke risk reduction in patients with nonvalvular atrial fibrillation
(NVAF). Data from diverse clinical practice settings will help establish whether the risk …

Background: Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation
(AF) but increases the risk for hemorrhage. Dabigatran is a fixed-dose, oral direct thrombin …

Background The recent availability of dabigatran, a novel oral anticoagulant, provided a new
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …

Objectives: This study sought to compare the net clinical benefit of dabigatran 110 mg bid
and 150 mg bid with that of warfarin in patients with atrial fibrillation (AF). Background: In …